Are you Dr. DeVore?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 52 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
9700 Tunbridge LN
Knoxville, TN 37922Phone+1 865-599-5543Fax+1 865-934-5801
Summary
- Dr. Russell DeVore III, MD is an oncologist in Knoxville, Tennessee. He is currently licensed to practice medicine in Tennessee, Kentucky, and North Carolina. He is affiliated with Fort Sanders Regional Medical Center and Sweetwater Hospital.
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1990
Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 1984 - 1987
West Virginia University School of MedicineClass of 1984
Certifications & Licensure
TN State Medical License 1987 - 2022
KY State Medical License 2000 - 2019
NC State Medical License 1985 - 1988- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Start of enrollment: 2013 Sep 09
- Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Start of enrollment: 2013 Oct 01
- Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Publications & Presentations
PubMed
- 96 citationsPhase II Trial of Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Trial 1597Gregory A. Masters, Lieven Declerck, Charles D. Blanke, Alan Sandler, Russell F. DeVore
Journal of Clinical Oncology. 2003-04-15 - 29 citationsPhase II trial of sorafenib and erlotinib in advanced pancreatic cancer.Dana Backlund Cardin, Laura W. Goff, Chung I. Li, Yu Shyr, Charles Winkler
Cancer Medicine. 2014-06-01 - 158 citationsA multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.Mace L. Rothenberg, V D O John Cox, Russell F. DeVore, John D. Hainsworth, Richard Pazdur
Cancer. 1999-02-15
Professional Memberships
- Member
